Rossari Biotech Limited — PPTs, 28-04-2026: Investor Presentation

Here's a concise, retail-friendly summary of Rossari Biotech's Q4 and FY26 investor presentation:

**Business Performance:** Rossari Biotech delivered stellar Q4 and FY26 results, reporting its highest-ever quarterly and annual revenue, EBITDA, and PAT. Q4 revenue grew 18.2% YoY to Rs. 684.9 Cr, with full-year FY26 revenue up 15.2% to Rs. 2,396.4 Cr. All core segments – Home, Personal Care & Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health & Nutrition (AHN) – showed healthy double-digit growth, underscoring portfolio strength. Losses in Institutional and B2C segments narrowed due to optimization.

**Growth Drivers & Strategy:** The company is driving growth through disciplined execution, customer-led innovation, and profitable expansion. Capacity is expanding, notably with Unitop commissioning 15,000 MTPA ethoxylation capacity at Dahej, bringing total to 66,000 MTPA. A new, advanced R&D facility at Koparkhairane is now operational, boosting innovation.

**Recent Developments:** Aside from capacity expansion and the new R&D center, the Board has proposed a dividend of Re. 0.50 per share for FY26.

**Key Financial Metrics:** Q4 FY26 PAT soared 33.7% to Rs. 46.0 Cr. Full-year FY26 PAT was Rs. 149.2 Cr, a 9.4% increase. Diluted EPS for FY26 stood at Rs. 26.9.

**Management Outlook:** Management remains confident in margin recovery via strategic pricing and operating leverage. They see Rossari well-positioned to become an integrated, impactful specialty chemicals platform, delivering sustained shareholder value.